You are here

Coronary Intervention & Surgery

 - United_States_Map

Prices for PCIs differ significantly in various parts of the U.S., according to a report released on July 16 from the Blue Cross Blue Shield Association. Within the same metropolitan area, costs varied by as much as 532 percent.

 - Stent roundtable

A randomized trial in Spain found an everolimus-eluting stent (EES) was more effective than a drug-eluting balloon (DEB) in treating patients with drug-eluting stent in-stent restenosis. One year after the procedures, the primary endpoint of cardiac death, MI and target vessel revascularization occurred in 10 percent of the EES group and 18 percent of the DEB group. The difference was statistically significant.

 - Money down the drain

An intraprocedural thrombotic event in a patient with non-ST-segment elevation acute coronary syndromes (NSTEACS) adds approximately $3,600 to hospital costs, according to an economic analysis of the ACUITY trial that was published in the July issue of Catheterization and Cardiovascular Interventions.

 - Court - Law

The U.S. Department of Justice (DOJ) closed its investigation into Abiomed’s marketing of the Impella 2.5 device without taking any action against the company, according to an Abiomed news release on June 29.

 - thumbs up, approval, thumb

The FDA approved cangrelor on June 22 for adults undergoing PCI. The intravenous medication is an antiplatelet drug and is intended to prevent blood clots.


More Stories

Long-term follow-up finds drug-eluting stents safer, more effective than bare-metal stents

After a median follow-up period of 3.8 years, drug-eluting stents were more effective than bare-metal stents and were associated with fewer instances of stent thrombosis, according to a meta-analysis of 51 randomized, controlled trials.

Ezetimibe plus simvastatin improves cardiovascular outcomes after ACS

Patients with acute coronary syndrome who received ezetimibe in addition to statin therapy had improvements in cardiovascular outcomes and a lowering of low-density lipoprotein (LDL) cholesterol, according to a double-blind, randomized controlled trial.

J&J pockets almost $2B with Cordis sale

Johnson & Johnson accepted nearly $2 billion from Cardinal Health for its pioneering stent business. The acquisition of Cordis is expected to close in late 2015.

Remote ischemic preconditioning reduces rate of acute kidney injury after cardiac surgery

Patients undergoing cardiac surgery who received remote ischemic preconditioning had a significant reduction in the rate of acute kidney injury and the use of renal replacement therapy, according to a multicenter, double-blind, randomized trial in Germany.

Benefit-risk assessment tilts toward low-dose aspirin after PCI

An analysis of TRANSLATE-ACS data supports current guideline recommendations to prescribe low-dose aspirin to patients who underwent PCI and received dual antiplatelet therapy. The study was published online May 20 in Circulation.

PCI perplexities: Radial shunned despite bleeding advantage

Operators more often chose transfemoral over transradial PCI in a patients with higher predicted bleeding risks, despite evidence of fewer bleeding complications with the latter approach. Transfemoral PCI patients also tended to be sicker, according to this observational study.

Truly informed PCI patients

Sometimes a finding doesn’t reach the bar for statistical significance, but that doesn’t mean it isn’t intriguing. Interventional cardiologists might take note of a study on informed decision making that showed them more likely to touch on key elements than general cardiologists.

Informed patients more likely to opt against angiography, PCIs

Patients who were more fully informed about angiography and the possibility of PCI were more likely to decide against it, a study published online May 18 in JAMA Internal Medicine found. Overall, the cardiologist-patient discussions were short and incomplete.

Quitting smoking after PCI leads to quality of life improvements

More than a quarter of patients undergoing PCI are smokers at the time of treatment. If they quit smoking following the procedure, they are more likely to have improvements in quality of life and have less chest pain and angina than if they continue to smoke, according to a prospective analysis of a PCI registry.

Hospital traits may explain deficiencies in PCI rehab referrals

Only about 60 percent of PCI patients get referred to a cardiac rehabilitation program, according to a recent study, and the barrier is more likely due to hospital characteristics than insurance. 

SCAI.15: In practice, prasugrel use may not mimic trials

Cardiologists in real-world practice may not be optimizing the benefit of prasugrel in patients undergoing PCI but they also don’t appear to be putting them in harm’s way, according to results released May 8 at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 scientific session in San Diego.

SCAI.15: Orbital atherectomy sustains its benefits at 2 years

An atherectomy device that “sands” calcified lesions in coronary arteries before stenting proved to be effective and durable at two years, and possibly even cost-effective, in a late-breaking clinical trial unveiled on May 7.

GI events are most common bleeding complication 1 year after PCI

One year after patients underwent PCIs, approximately 1 percent had gastrointestinal bleeding, which was associated with an increased risk for all-cause mortality and the composite of death, MI or stroke.

Similar survival rates for children who receive therapeutic hypothermia or normothermia

Children who remained unconscious after out-of-hospital cardiac arrest had similar survival rates and cognitive functioning if they received therapeutic hypothermia or therapeutic normothermia, according to a randomized trial.

A safer cath lab

The cardiology community has heeded the call to protect patients from radiation exposure in the cath lab. Now it is time to focus on the operators and staff.

Synergy clears noninferiority bar in EVOLVE II

An everolimus-eluting stent with a bioresorbable coating held its own clinically against a durable polymer drug-eluting stent in the pivotal EVOLVE II trial, findings that may be used to determine regulatory approval of the bioresorbable device.

Diabetes patients undergoing CABG have increased risk of death

Patients with type 1 diabetes had double the risk of death after undergoing CABG compared with a group that did not have diabetes, according to an observational, nationwide population-based cohort study.

Potential harms from cath lab radiation may include heart disease

Interventional cardiologists and nurses worry about cardiovascular disease developing in their patients. A study that looked at long-term radiation exposure to cath lab operators and staff may prompt them to add themselves to that list.

OriGen Biomedical recalls ECMO catheters

OriGen Biomedical voluntarily recalled a lot of its 51 VV13F Reinforced Dual Lumen ECMO Catheters, according to the company and the FDA.

NIH launches largest trial to date for HIV-related cardiovascular disease

The NIH has launched a randomized, multicenter, international study to see if statins can reduce the risk of cardiovascular disease in HIV patients. As of now, no therapies have been found to lower cardiovascular risk in this patient population.